Advertisement

European Journal of Clinical Pharmacology

, Volume 43, Issue 6, pp 571–579 | Cite as

The relevance of residence time theory to pharmacokinetics

  • M. Weiss
Special Article

Key words

Pharmacokinetics, Residence time model, volume of distribution, curve moments, parameter estimation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Popper KR (1963) Conjectures and refutations. Routledge and Kegan Paul, LondonGoogle Scholar
  2. 2.
    Yamaoka J, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558Google Scholar
  3. 3.
    Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074Google Scholar
  4. 4.
    Dost FH (1958) Über ein einfaches statistisches Dosis-Umsatzgesetz. Klin Wochenschr 36: 655–657Google Scholar
  5. 5.
    Rescigno A, Segre G (1966) Drug and tracer kinetics. Blaisdell, Waltham, MassachusettsGoogle Scholar
  6. 6.
    Shipley RA, Clark RE (1972) Tracer methods for in vivo kinetics. Theory and application. Academic Press, New YorkGoogle Scholar
  7. 7.
    Lassen NA, Perl W (1979) Tracer kinetic methods in medical physiology. Raven Press, New YorkGoogle Scholar
  8. 8.
    Chanter DO (1985) The determination of mean residence time using statistical moments: is it correct? J Pharmacokinet Biopharm 13: 93–100Google Scholar
  9. 9.
    Banakar UV (1986) A closer look at the mean residence time (MRT) concept based on statistical moments. Drug Dev Ind Pharm 12: 1675–1683Google Scholar
  10. 10.
    Benet LZ (1985) Mean residence time in the body versus mean residence time in the central compartment. J Pharmacokinet Biopharm 13: 555–558Google Scholar
  11. 11.
    Landaw EM, Katz D (1985) Comments on mean residence time determination. J Pharmacokinet Biopharm 13: 543–547Google Scholar
  12. 12.
    Gillespie WR, Veng-Pedersen P (1985) The determination of mean residence time using statistical moments: it is correct. J Pharmacokinet Biopharm 13: 549–554Google Scholar
  13. 13.
    Brockmeier D (1986) Model-free evaluation and mean-time concept in pharmacokinetics. Meth Find Exp Clin Pharmacol 8: 593–602Google Scholar
  14. 14.
    Weiss M, Förster W (1979) Pharmacokinetic model based on circulatory transport. Eur J Clin Pharmacol 16: 287–293Google Scholar
  15. 15.
    Veng-Pedersen P (1988) Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations. J Pharmacokinet Biopharm 16: 413–471Google Scholar
  16. 16.
    Veng-Pedersen P (1989) Mean time parameters in pharmacokinetics: definition, computation and clinical implications (parts I and II). Clin Pharmacokinet 17: 345–366Google Scholar
  17. 17.
    Weiss M (1986) Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions: I. Log-convex drug disposition curves. J Pharmacokinet Biopharm 14: 635–657Google Scholar
  18. 18.
    Weiss M (1987) Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions: II. Log-concave concentration-time curves following oral administration. J Pharmacokinet Biopharm 15: 57–74Google Scholar
  19. 19.
    Weiss M (1985) Theorems on log-convex disposition curves in drug and tracer kinetics. J Theor Biol 116: 355–368Google Scholar
  20. 20.
    Henthorn TK, Avram MJ, Krejcie TC (1989) Intravascular mixing and drug distribution: the concurrent disposition of thiopental and indocyanine green. Clin Pharmacol Ther 45: 56–65Google Scholar
  21. 21.
    Perrier D, Mayersohn M (1982) Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 71: 372–373Google Scholar
  22. 22.
    Karol MD (1990) Mean residence time and the meaning of AUMC/AUC. Biopharm Drug Dispos 11: 179–181Google Scholar
  23. 23.
    Weiss M (1983) Use of gamma distributed residence times in pharmacokinetics. Eur J Clin Pharmacol 25: 695–702Google Scholar
  24. 24.
    Tucker GT, Jackson PR, Storey GCA, Holt DW (1984) Amiodarone disposition: polyexponentials, power and gamma functions. Eur J Clin Pharmacol 26: 655–656Google Scholar
  25. 25.
    Kallai-Sanfacon MA, Norwich KH, Steiner G (1978) A new approach to the measurement of glycerol turnover. Can J Physiol Pharmacol 56: 934–939Google Scholar
  26. 26.
    Sainsbury EJ, Ashley JJ (1986) Curve-fitting in pharmacokinetics – a comparison between gamma and exponential fits. Eur J Clin Pharmacol 30: 243–244Google Scholar
  27. 27.
    Weiss M (1991) Residence time distributions in pharmacokinetics: behavioral and structural models. In: D'Argenio DZ (ed) Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. Plenum Press, New York, pp 89–101Google Scholar
  28. 28.
    Piotrovskii VK (1987) Pharmacokinetic stochastic model with Weibull-distributed residence times of drug molecules in the body. Eur J Clin Pharmacol 32: 515–523Google Scholar
  29. 29.
    Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8: 509–534Google Scholar
  30. 30.
    Weiss M (1981) Residence time and accumulation of drugs in the body. Int J Clin Pharmacol 19: 123–135Google Scholar
  31. 31.
    Weiss M (1984) Model-independent assessment of accumulation kinetics based on moments of drug disposition curves. Eur J Clin Pharmacol 27: 355–359Google Scholar
  32. 32.
    Weiss M (1988) Washout time versus mean residence time. Pharmazie 43: 126–127Google Scholar
  33. 33.
    Steinijans VW, Diletti E (1983) Statistical analysis of the bioavailability studies: parameterc and nonparametric confidence intervals. Eur J Clin Pharmacol 24:127–136Google Scholar
  34. 34.
    Weiss M (1990) Recirculatory models: a rigorous basis for a pharmacokinetic theory. In: Breimer DD, Crommelin DJA, Midha J (eds) Topics in Pharmaceutical Sciences, F.I.P., The Hague, pp 415–427Google Scholar
  35. 35.
    Weiss M (1991) Nonidentity of the steady-state volumes of distribution of the eliminating and noneliminating system. J Pharm Sci 80: 908–910Google Scholar
  36. 36.
    Weiss M, Pang KS (1990) The dynamics of drug distribution as assessed by the second and third curve moments. Eur J Pharmacol 183: 611–612Google Scholar
  37. 37.
    Weiss M, Pang KS (1992) Dynamics of drug distribution. I. Role of the second and third curve moment. J Pharmacokinet Biopharm 20: 253–278Google Scholar
  38. 38.
    Weiss M (1982) Moments of physiological transit time distributions and the time course of drug disposition in the body. J Math Biol 15: 305–318Google Scholar
  39. 39.
    Weiss M (1983) Hemodynamic influences upon the variance of disposition residence time distribution. J Pharmacokinet Biopharm 11: 63–75Google Scholar
  40. 40.
    Cutler DJ (1978) Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J Pharm Pharmacol 30: 476–478Google Scholar
  41. 41.
    Weiss M (1990) Theoretische Pharmakokinetik. Verlag Gesundheit, BerlinGoogle Scholar
  42. 42.
    Von Hattingberg HM, Brockmeier D (1979) A method for in vivo-in vitro correlation using the additivity of mean times in biopharmaceutical models. In: Rietbrock N, Woodcock BG, Neuhaus G (eds) Methods in clinical pharmacology. Vieweg, BraunschweigGoogle Scholar
  43. 43.
    Tanigawara Y, Yamaoka K, Nakagawa T, Uno T (1982) New method for the evaluation of in vitro dissolution time and disintegration time. Chem Pharm Bull 30: 1088–1090Google Scholar
  44. 44.
    Graffner C, Nicklasson M, Lindgren J-E (1984) Correlations between in vitro dissolution rate and bioavailability of alaproclate tablets. J Pharmacokinet Biopharm 12: 367–380Google Scholar
  45. 45.
    Brockmeier D, Dengler HJ, Voegele D (1985) In vitro-in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example. Eur J Clin Pharmacol 28: 291–300Google Scholar
  46. 46.
    Van Rossum JM, Ginneken CAM (1980) Pharmacokinetic system dynamics. In: Gladtke E, Heimann H (eds) Pharmacokinetics. Fischer, StuttgartGoogle Scholar
  47. 47.
    Kubota K, Ishizaki T (1986) A diffusion-diffusion model for percutaneous drug absorption. J Pharmacokinet Biopharm 14: 409–439Google Scholar
  48. 48.
    Weiss M (1986) Metabolite residence time: influence of the first pass effect. Br J Clin Pharmacol 22: 121–122Google Scholar
  49. 49.
    Weiss M (1990) Use of metabolite AUC data in bioavailability studies to discriminate between absorption and first-pass extraction. Clin Pharmacokinet 18: 419–422Google Scholar
  50. 50.
    Weiss M (1988) A general model of metabolite kinetics following intravenous and oral administration of the parent drug. Biopharm Drug Dispos 9: 159–176Google Scholar
  51. 51.
    Brockmeier D, Ostrowski J (1985) Mean time and first-pass metabolism. Eur J Clin Pharmacol 29: 45–48Google Scholar
  52. 52.
    Cheng H, Jusko WJ (1990) Mean residence times of multicompartmental drug undergoing reversible metabolism. Pharm Res 7: 103–107Google Scholar
  53. 53.
    D'Argenio DZ, Katz D (1983) Sampling strategies for noncompartmental estimation of mean residence time. J Pharmacokinet Biopharm 11: 435–446Google Scholar
  54. 54.
    Nüesch EA (1984) Noncompartmental approach in pharmacokinetics using moments. Drug Metab Rev 15: 103–131Google Scholar
  55. 55.
    Smith IL, Schentag JJ (1984) Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci 73: 281–282Google Scholar
  56. 56.
    Pfeffer M (1984) Estimation of mean residence time from data obtained when multiple-dosing steady state has been reached. J Pharm Sci 73: 854–856Google Scholar
  57. 57.
    Watari N, Benet LZ (1989) Determination of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs. J Pharmacokinet Biopharm 17: 593–599Google Scholar
  58. 58.
    Voegele D, von Hattingberg H, Brockmeier D (1981) Ein einfaches Verfahren zur Ermittlung von in-vitro/in-vivo Zusammenhängen in der Galenik. Acta Pharm Technol 27: 115–120Google Scholar
  59. 59.
    Siegel R (1986) The urinary elimination “time lag”: determination of the mean residence time from drug accumulation in the urine during infusion. J Pharm Sci 75: 627–628Google Scholar
  60. 60.
    Yeh KC, Small RD (1989) Pharmacokinetic evaluation of stable piecewise cubic polynomials as numeric integration functions. J Pharmacokinet Biopharm 17: 721–740Google Scholar
  61. 61.
    Dunne A, King P (1989) Estimation of noncompartmental parameters: a technical note. J Pharmacokinet Biopharm 17: 131–137Google Scholar
  62. 62.
    Holford N (1992) MKMODEL: an extended least squares modelling program. Cambridge, England, BiosoftGoogle Scholar
  63. 63.
    Wagner JG (1988) Types of mean residence times. Biopharm Drug Dispos 9: 41–57Google Scholar
  64. 64.
    Chiou WL (1989) The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Clin Pharmacokinet 17: 175–199Google Scholar
  65. 65.
    Weiss M (1984) Definition of pharmacokinetic parameters: influence of the sampling site. J Pharmacokinet Biopharm 12: 167–176Google Scholar
  66. 66.
    Cutler DJ (1987) Definition of mean residence times in pharmacokinetics. Biopharm Drug Dispos 8: 87–97Google Scholar
  67. 67.
    Nakashima E, Benet LZ (1987) Simulation studies of mean residence time for drugs with peripheral elimination: application to nitroglycerin. J Pharm Sci 76: S106Google Scholar
  68. 68.
    Nakashima E, Benet LZ (1988) General treatment of mean residence time, clearance and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 16: 475–492Google Scholar
  69. 69.
    DiStefano III JJ, Landaw EM (1984) Multiexponential, multicompartmental, and noncom partmental modeling: I. Methodological limitations and physiological interpretations. Am J Physiol 246: R651-R664Google Scholar
  70. 70.
    Vaughan DP, Hope I (1979) Applications of a recirculatory stochastic pharmacokinetic model: limitations of compartmental models. J Pharmacokinet Biopharm 7: 207–225Google Scholar
  71. 71.
    Weiss M (1991) Potential errors in conventional single-dose pharmacokinetic studies. Naunyn-Schmiedeberg's Arch Pharmacol 343: R4Google Scholar
  72. 72.
    Rescigno A, Beck JS (1987) The use and abuse of models. J Pharmacokinet Biopharm 15: 327–340Google Scholar
  73. 73.
    Karlin S, Taylor MM (1975) A first course in stochastic processes. Academic Press, New YorkGoogle Scholar
  74. 74.
    Barlow RE, Proschan F (1975) Statistical theory of reliability and life testing. Holt, Rinehart and Winston, New YorkGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • M. Weiss
    • 1
  1. 1.Martin Luther University Halle-WittenbergDepartment of Pharmacology and ToxicologyHalle/SaaleGermany

Personalised recommendations